Literature DB >> 25982165

Mesenchymal stromal cells and the innate immune response.

Katarina Le Blanc1, Lindsay C Davies2.   

Abstract

Mesenchymal stromal cells (MSC) have been exploited for their immunomodulatory properties in the treatment of a number of immune-based disorders, including Graft versus Host Disease (GvHD) and type 1 diabetes. The mechanisms for inducing therapeutic effect still remain largely unknown however, with research focused on understanding how MSCs interact with individual immune cell subsets. Within this review we address what is known about the interactions of MSCs with cells of the innate immune system, how they respond to their microenvironment and how this relates to therapeutic effects we see both within in vivo animal models and in clinical trials.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunomodulation; Inflammation; Innate immunity; Mesenchymal stromal cells

Mesh:

Substances:

Year:  2015        PMID: 25982165     DOI: 10.1016/j.imlet.2015.05.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  76 in total

Review 1.  Clinical trials of intervertebral disc regeneration: current status and future developments.

Authors:  Yi Sun; Victor Y Leung; Kenneth M Cheung
Journal:  Int Orthop       Date:  2018-11-29       Impact factor: 3.075

2.  Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration.

Authors:  Yan Li; John Fung; Feng Lin
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 3.  Bone repair with skeletal stem cells: rationale, progress to date and clinical application.

Authors:  Elena A Jones; Peter V Giannoudis; Dimitrios Kouroupis
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-01       Impact factor: 5.346

4.  Mechanisms of Immune Suppression Utilized by Canine Adipose and Bone Marrow-Derived Mesenchymal Stem Cells.

Authors:  Lyndah Chow; Valerie Johnson; Jonathan Coy; Dan Regan; Steven Dow
Journal:  Stem Cells Dev       Date:  2017-01-24       Impact factor: 3.272

5.  The effect of local anesthetic on pro-inflammatory macrophage modulation by mesenchymal stromal cells.

Authors:  Andrea Gray; Ileana Marrero-Berrios; Jonathan Weinberg; Devasena Manchikalapati; Joseph SchianodiCola; Rene S Schloss; Joel Yarmush
Journal:  Int Immunopharmacol       Date:  2016-02-06       Impact factor: 4.932

Review 6.  Exosomes in perspective: a potential surrogate for stem cell therapy.

Authors:  Ke Ren
Journal:  Odontology       Date:  2018-10-15       Impact factor: 2.634

7.  Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Authors:  Mehdi Najar; Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Fabrice Journe; Laurence Lagneaux
Journal:  Inflamm Res       Date:  2016-10-25       Impact factor: 4.575

Review 8.  Challenges in vascular tissue engineering for diabetic patients.

Authors:  Jhilmil Dhulekar; Agneta Simionescu
Journal:  Acta Biomater       Date:  2018-02-01       Impact factor: 8.947

9.  The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria.

Authors:  Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Laurence Lagneaux; Mehdi Najar
Journal:  Inflamm Res       Date:  2016-03-08       Impact factor: 4.575

10.  In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.

Authors:  Yazmin I Rovira Gonzalez; Patrick J Lynch; Elaine E Thompson; Brian G Stultz; Deborah A Hursh
Journal:  Cytotherapy       Date:  2016-07-12       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.